Lysophosphatidylcholine- and MCP-1-induced chemotaxis of monocytes requires potassium channel activity.
One of the earliest cellular responses in atherogenesis is the focal recruitment of circulating monocytes, while the most important atherogenic chemoattractants are monocyte chemoattractant protein-1 (MCP-1) and lysophosphatidylcholine (LPC). Invading monocytes transform into activated macrophages and foam cells, which stimulate inflammatory processes and promote atherosclerosis. In this study, we have searched for common mechanisms involved in MCP-1- and LPC-stimulated monocyte migration. We have found that migration of THP-1 monocytes stimulated with MCP-1 was reduced upon inhibition of G(i/o) proteins with pertussis toxin and upon inhibition of platelet activating factor receptors with BN52021, whereas LPC-stimulated monocyte chemotaxis remained unaffected by both inhibitors. Furthermore, Cl(-) channels were only required for MCP-1-induced chemotaxis. However, activity of voltage-gated K+ channels and of Ca2+-activated K+ channels was found to be involved in migration of monocytes stimulated with either MCP-1 or LPC. Inhibition of voltage-gated K+ channels with 4-aminopyridine or margatoxin partially inhibited MCP-1- and LPC-stimulated migration of monocytes. Blockade of Ca2+-activated K+ channels with TRAM-34 also partially reduced migration of MCP-1- and LPC-stimulated monocytes. Simultaneous inhibition of voltage-gated and Ca2+-activated K+ channels abolished MCP-1- and LPC-induced chemotaxis of monocytes. Thus, K+ channel inhibition may represent a novel powerful strategy to reduce monocyte infiltration and subsequent inflammation in atherosclerosis.
Schilling
Tom
T
Division of Basic Medical Sciences, St. George's University of London, Cranmer Terrace, London, SW17 0RE, UK.
Eder
Claudia
C
D050197:Atherosclerosis / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D018932:Chemokine CCL2 / Q000378:metabolism*; D002634:Chemotaxis, Leukocyte / Q000502:physiology*; D006801:Humans; D007249:Inflammation / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008244:Lysophosphatidylcholines / Q000378:metabolism*; D009000:Monocytes / Q000378:metabolism*; D015221:Potassium Channels / Q000378:metabolism*
C111835:CCL2 protein, human; D018932:Chemokine CCL2; D008244:Lysophosphatidylcholines; D015221:Potassium Channels
Int J Cardiol. 1997 Dec 31;62 Suppl 2:S85-90
9488199
Pflugers Arch. 1995 Sep;430(5):802-7
7478936
Blood. 2005 Feb 1;105(3):1127-34
15383458
Curr Opin Lipidol. 2001 Apr;12(2):175-80
11264989
Pflugers Arch. 2009 Sep;458(5):981-92
19437033
J Cell Physiol. 2009 Nov;221(2):325-34
19562685
Arterioscler Thromb Vasc Biol. 2002 Dec 1;22(12):2049-53
12482833
Annu Rev Pathol. 2006;1:297-329
18039117
J Clin Invest. 1997 Nov 15;100(10):2552-61
9366570
J Cell Physiol. 2006 Jan;206(1):86-94
15965951
J Clin Invest. 2008 Sep;118(9):3025-37
18688283
J Am Coll Cardiol. 2006 Apr 18;47(8 Suppl):C7-12
16631513
Curr Med Chem. 2007;14(30):3209-20
18220755
J Membr Biol. 1996 Jul;152(2):141-57
9139125
Nature. 1998 Aug 27;394(6696):894-7
9732872
Nat Rev Immunol. 2006 Jul;6(7):508-19
16778830
Pflugers Arch. 2007 Jul;454(4):559-63
17318643
Nat Struct Biol. 2002 Sep;9(9):696-703
12172537
Clin Exp Immunol. 2004 Dec;138(3):453-9
15544622
Pflugers Arch. 2007 Jan;453(4):421-32
17021798
Am J Physiol. 1997 Jan;272(1 Pt 2):H17-24
9038918
J Membr Biol. 1996 Jul;152(2):117-30
9139123
Proc Natl Acad Sci U S A. 1988 Apr;85(8):2805-9
3357891
J Rehabil Res Dev. 2006 Jan-Feb;43(1):111-22
16847777
J Lipid Res. 2005 Jul;46(7):1405-15
15834123
BioDrugs. 2004;18(5):329-41
15377175
J Lipid Res. 1999 Jun;40(6):988-93
10357830
J Physiol. 2004 May 15;557(Pt 1):105-20
15020687
Physiol Rev. 2003 Oct;83(4):1069-112
14506301